Julia R. Brinton

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Avid Bioservices (Nasdaq: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, on its definitive merger agreement to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.

Cooley advised Reverence Capital Partners’ portfolio company Transact Campus, an innovative campus technology and payment solutions company, on a definitive agreement signed by Reverence Capital Partners to sell Transact to Roper Technologies for $1.6 billion.

Cooley advised Mott Corporation – a microfiltration business specializing in the design, customization, and manufacturing of sintered porous metal components and engineered solutions used in fluidic applications – on its definitive agreement to sell to IDEX Corporation for cash consideration of $1 billion, subject to customary adjustments.

Cooley advised Yardi Systems, a large software corporation with offices worldwide, in connection with WeWork’s emergence from Chapter 11 and completion of WeWork’s global operational and financial restructuring.